Bio-Thera partners with Pharmapark in Russia/CIS on BAT2206, a Stelara biosimilar

China’s Bio-Thera Solutions (688177:SH) has reached a licensing and supply agreements with Pharmapark for BAT2206, its ustekinumab biosimilar, under which Pharmapark will have exclusive rights to distribute and market the drug with a status of a local product in Russia and other Commonwealth of Independent States (CIS) countries.

Bio-Thera and Pharmapark’s partnership was initiated around a licensing and supply agreement for Pharmapark to distribute and market BAT2506, a golimumab biosimilar, in Russia and other CIS countries.

BAT2206 is a proposed biosimilar to Johnson & Johnson (NYSE: JNJ) subsidiary Jansen’s Stelara, which is currently approved in the USA for the treatment of active psoriatic arthritis (PsA) in adults, alone or in combination with MTX, the treatment of patients six years or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, the treatment of moderately to severely active Crohn’s disease in adults, and the treatment of moderately to severely active ulcerative colitis in adults.